| Symbol | RYTM |
|---|---|
| Name | RHYTHM PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 222 BERKELEY STREET,12TH FLOOR, BOSTON, Massachusetts, 02116, United States |
| Telephone | +1 857 264-4280 |
| Fax | — |
| — | |
| Website | https://www.rhythmtx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001649904 |
| Description | Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The companys product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Additional info from NASDAQ: |
2026-07-02 20:52
Garfield Alastair 🟡 adjusted position in 2.1K shares (1 derivative) of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $110.41 Transaction Date: Jul 01, 2026 | Filing ID: 080397
Read more
2026-06-25 22:09
Director JEAN CHRISTOPHE 🟡 adjusted position in 6.0K shares (3 derivative) of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $107.55 Transaction Date: Jun 23, 2026 | Filing ID: 077867
Read more
2026-06-25 22:08
Director MCGIRR DAVID W J 🟡 adjusted position in 6.0K shares (3 derivative) of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $107.55 Transaction Date: Jun 23, 2026 | Filing ID: 077866
Read more
2026-06-25 22:06
Director TETRAULT LYNN A. 🟡 adjusted position in 6.0K shares (3 derivative) of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $107.55 Transaction Date: Jun 23, 2026 | Filing ID: 077864
Read more
2026-06-25 22:03
Director Arbuckle Stuart A 🟡 adjusted position in 6.0K shares (3 derivative) of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $107.55 Transaction Date: Jun 23, 2026 | Filing ID: 077863
Read more
2026-06-25 22:01
Director GOOD JENNIFER L 🟡 adjusted position in 6.0K shares (3 derivative) of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $107.55 Transaction Date: Jun 23, 2026 | Filing ID: 077862
Read more
2026-06-25 20:46
(99% Neutral) RHYTHM PHARMACEUTICALS, INC. (RYTM) Announces Regulatory Update
Read more
2026-06-24 20:15
Director TETRAULT LYNN A. 🟡 adjusted position in 37.0K shares (1 derivative) of RHYTHM PHARMACEUTICALS, INC. (RYTM) at $100.32 ($5.8M) Transaction Date: Jun 22, 2026 | Filing ID: 077305
Read more
2026-06-22 20:49
📋 LYNN TETRAULT (Director) plans to sell 37K shares of RHYTHM PHARMACEUTICALS, INC. (at $96.79 each, total $3.6M) Filed: Jun 22, 2026 | ID: 006392
Read more
2026-06-15 20:07
(90% Positive) RHYTHM PHARMACEUTICALS, INC. (RYTM) Provides Update on improvements for outcomes across BMI
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05183802 | An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syn… | — | Bardet-Biedl Syndrome (BBS) | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07671677 | BOdygUardian MOnitoriNg for ReCurrencE of AF | — | Atrial Fibrillation (AF) | Not_Yet_Recruiting | 2026-07-01 | 2028-04-01 | ClinicalTrials.gov |
| NCT05139329 | The ORCHESTRATE-Myocarditis Registry | — | Myocarditis | Not_Yet_Recruiting | 2026-01-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT06672861 | Development and Validation of the Kansas City Cardiac Dysautonomia Questionnair… | Na | Cardiac Dysautonomia | Not_Yet_Recruiting | 2026-01-01 | 2026-08-01 | ClinicalTrials.gov |
| NCT05575999 | Effectiveness of Bupivacaine, Ketorolac, Ketamine, vs Bupivacaine Alone in Redu… | Phase1 | Pain Management | Not_Yet_Recruiting | 2026-01-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT05158751 | Myocarditis Causing Premature Ventricular Contractions:Insights From the MAVERI… | — | Myocarditis | Not_Yet_Recruiting | 2026-01-01 | 2026-05-01 | ClinicalTrials.gov |
| NCT05464511 | Impact of Steerable Delivery Sheaths on Successful Closure of LA A With AMULET | Na | Atrial Fibrillation | Not_Yet_Recruiting | 2026-01-01 | 2026-12-01 | ClinicalTrials.gov |
| NCT07156578 | A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) | Phase2 | Hypothalamic Obesity | Enrolling_By_Invitation | 2025-11-10 | 2028-04-15 | ClinicalTrials.gov |
| NCT06783868 | Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhyt… | — | Atrial Fibrillation | Not_Yet_Recruiting | 2025-10-01 | 2027-06-01 | ClinicalTrials.gov |
| NCT06760546 | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-… | Phase3 | Hypothalamic Obesity | Recruiting | 2025-09-23 | 2028-03-13 | ClinicalTrials.gov |
| NCT05464940 | Impact of Intravenous Caffeine on Atrial Electrical Properties and Potential Ar… | Na | Atrial Fibrillation | Not_Yet_Recruiting | 2025-09-01 | 2026-06-01 | ClinicalTrials.gov |
| NCT06939478 | AI Powered Mapping Technology for Identifying Arrhythmias | — | Arrhythmias, Cardiac | Completed | 2025-08-27 | 2026-05-15 | ClinicalTrials.gov |
| NCT07118124 | Pediatric Adhesion and New Dermal Approach Study | Na | Syncope | Completed | 2025-08-15 | 2026-01-13 | ClinicalTrials.gov |
| NCT07041125 | Concomitant LAAC/AF Ablation (Watchman FLX Pro) | — | PFA Ablation and LAAC Procedures | Recruiting | 2025-06-01 | 2026-10-30 | ClinicalTrials.gov |
| NCT06878924 | Safety and Efficacy of Pulmonary Vein Isolation Using Pulsed-field Ablation (PF… | — | Atrial Fibrillation (AF) | Not_Yet_Recruiting | 2025-05-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT06174220 | Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic … | Phase2 | Arrhythmogenic Cardiomyopathy | Recruiting | 2025-03-21 | 2027-07-01 | ClinicalTrials.gov |
| NCT06772597 | A Study of Setmelanotide in Patients With Prader-Willi Syndrome | Phase2 | Prader-Willi Syndrome | Active_Not_Recruiting | 2025-03-04 | 2027-10-31 | ClinicalTrials.gov |
| NCT07190963 | MindRhythm Detection of Concussion and Recovery Study | — | mTBI - Mild Traumatic Brain Injury | Recruiting | 2025-01-28 | 2027-03-30 | ClinicalTrials.gov |
| NCT06669637 | Amplify EP Registry | — | Atrial Fibrillation | Not_Yet_Recruiting | 2024-11-22 | 2026-12-01 | ClinicalTrials.gov |
| NCT05719272 | HeadPulse Large Vessel Occlusion Validation Study | — | Stroke, Ischemic | Unknown | 2024-11-16 | 2025-05-30 | ClinicalTrials.gov |
| NCT06374264 | Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spect… | Na | Neuromyelitis Optica Spectrum Disorder | Enrolling_By_Invitation | 2024-11-12 | 2026-12-31 | ClinicalTrials.gov |
| NCT06596135 | Open-Label Extension Study of Setmelanotide | Phase3 | Obesity Associated With Defects in Leptin-melanocortin Pathway | Enrolling_By_Invitation | 2024-10-21 | 2027-10-30 | ClinicalTrials.gov |
| NCT06465706 | Assessing the Safety and Efficacy of the LAmbre™ Plus Device | Na | Atrial Fibrillation | Not_Yet_Recruiting | 2024-09-01 | 2030-01-31 | ClinicalTrials.gov |
| NCT06488820 | Safety and Efficacy of Pulsed-field Ablation for Atrial Fibrillation in High Ve… | — | Atrial Fibrillation | Terminated | 2024-08-29 | 2025-04-04 | ClinicalTrials.gov |
| NCT06046443 | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic … | Phase2 | Hypothalamic Obesity | Completed | 2024-07-11 | 2026-02-09 | ClinicalTrials.gov |
| NCT06436924 | Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Devi… | — | Atrial Fibrillation | Recruiting | 2024-05-14 | 2026-03-30 | ClinicalTrials.gov |
| NCT06335082 | A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety… | — | Atrial Fibrillation | Enrolling_By_Invitation | 2024-04-24 | 2027-01-30 | ClinicalTrials.gov |
| NCT05452356 | Testing VIRTUES Patient Care Sets in Cardiac Patients (VIRTUES Cardiac Care) | — | Heart Diseases | Recruiting | 2024-04-18 | 2028-09-30 | ClinicalTrials.gov |
| NCT06420622 | INDIcators for Clarifying the bAckground of exTreme Obesity in childRen | — | Gene Abnormality | Recruiting | 2024-04-15 | 2026-03-31 | ClinicalTrials.gov |
| NCT06354777 | REView of ProcEdural FactoRs and Outcomes After Atrial Fibrillation Ablation Wi… | — | Atrial Fibrillation | Active_Not_Recruiting | 2024-04-03 | 2026-12-30 | ClinicalTrials.gov |
| NCT07092774 | Real-world Safety and Effectiveness Registry of Catheter Ablation of Paroxysmal… | — | Paroxysmal Atrial Fibrillation (PAF) | Active_Not_Recruiting | 2024-04-01 | 2025-12-01 | ClinicalTrials.gov |
| NCT06239116 | A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment | Phase1 | Hypothalamic Obesity | Recruiting | 2024-03-05 | 2028-11-01 | ClinicalTrials.gov |
| NCT06324201 | The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use … | — | Paroxysmal Atrial Fibrillation | Recruiting | 2024-02-27 | 2028-03-01 | ClinicalTrials.gov |
| NCT06289413 | Autonomic Dysfunction in Patients Following Bariatric Surgery: The ADiPOSE Study | — | Autonomic Dysfunction | Recruiting | 2024-02-12 | 2025-12-01 | ClinicalTrials.gov |
| NCT06239064 | Early Genetic Identification of Obesity | — | Obesity, Childhood | Active_Not_Recruiting | 2024-01-24 | 2027-03-01 | ClinicalTrials.gov |
| NCT06134739 | Arterial Embolism After Catheter Ablation of Atrial Fibrillation. ATRIAL FIBRIL… | — | Arrhythmia | Unknown | 2024-01-02 | 2024-12-01 | ClinicalTrials.gov |
| NCT06199414 | Vascular Closure With Novel External Compression Device: The LockeT Study | — | Atrial Fibrillation | Unknown | 2024-01-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT05813704 | Coronary Crossing System in Patients With Coronary Chronic Total Occlusions | Na | Chronic Total Occlusion of Coronary Artery | Unknown | 2023-11-07 | 2025-05-01 | ClinicalTrials.gov |
| NCT06342492 | Conduction System Vs Surgical Left Ventricular Epicardial Pacing For Coronary S… | — | Heart Failure With Reduced Ejection Fraction | Recruiting | 2023-11-07 | 2024-12-01 | ClinicalTrials.gov |
| NCT06051539 | Outcomes and Health Economics of Stroke Using Rhythmic Auditory Stimulation | Na | Chronic Stroke | Completed | 2023-10-10 | 2025-10-01 | ClinicalTrials.gov |
| NCT05826665 | Observational Study to Examine the Procedural and Outcomes of AF Ablation Assis… | — | Persistent Atrial Fibrillation | Recruiting | 2023-10-02 | 2025-07-31 | ClinicalTrials.gov |
| NCT06078735 | Vascular Closure With a Device Compared to Manual Compression After Atrial Fibr… | Na | Atrial Fibrillation | Recruiting | 2023-10-02 | 2024-12-01 | ClinicalTrials.gov |
| NCT06055751 | Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Im… | — | Aortic Stenosis | Recruiting | 2023-09-22 | 2025-12-01 | ClinicalTrials.gov |
| NCT06003790 | Facilitators and Barriers to the Clinical Implementation of MR-001 | Na | Chronic Stroke | Completed | 2023-08-29 | 2024-04-30 | ClinicalTrials.gov |
| NCT05464537 | Efficacy Rate of Unipolar Polarity Switch for Lesion Assessment in Pulmonary Ve… | Na | Atrial Fibrillation | Terminated | 2023-08-28 | 2024-11-27 | ClinicalTrials.gov |
| NCT06052358 | Left Atrial Appendage Closure With WATCHMAN FLX Device in Recurrent Gastrointes… | — | Atrial Fibrillation | Terminated | 2023-08-23 | 2025-06-11 | ClinicalTrials.gov |
| NCT06075628 | Long-Term Outcomes of LAA Contrast Flow in CT Scans After Endocardial LAA Closu… | — | Atrial Fibrillation | Recruiting | 2023-07-24 | 2025-12-01 | ClinicalTrials.gov |
| NCT05602740 | Detection of hEad Pulse for Ischemic StrOke Verification Study | — | Stroke, Acute | Unknown | 2023-06-15 | 2023-10-01 | ClinicalTrials.gov |
| NCT06061757 | Use of 4D-ICE in Conjunction With TEE for Left Atrial Appendage Closure | Na | Atrial Fibrillation | Recruiting | 2023-05-10 | 2025-12-31 | ClinicalTrials.gov |
| NCT05774756 | A Trial of Setmelanotide in Acquired Hypothalamic Obesity | Phase3 | Hypothalamic Obesity | Active_Not_Recruiting | 2023-04-26 | 2027-04-16 | ClinicalTrials.gov |
| NCT06188351 | Three Dimensional Navigation IntraCardiac Guidance Kit for Atrial Septal Punctu… | Na | Atrial Fibrillation | Unknown | 2023-04-24 | 2024-09-01 | ClinicalTrials.gov |
| NCT05450302 | Assessing the Predictive Value of High Frequency Algorithm of PURE EP for Low A… | — | Cardiac Arrhythmias | Unknown | 2023-04-01 | 2023-12-01 | ClinicalTrials.gov |
| NCT05818098 | Coronary Intravascular Lithotripsy System in Patients With Coronary Artery Calc… | Na | Coronary Artery Calcification | Unknown | 2023-03-29 | 2024-03-01 | ClinicalTrials.gov |
| NCT05606367 | Coronary Non-slip Balloon Catheter in Patients With Coronary Artery Stenosis(CR… | Na | Coronary Artery Stenosis | Unknown | 2023-01-03 | 2023-10-01 | ClinicalTrials.gov |
| NCT07674290 | Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic Obesity | Phase4 | Bardet Biedl Syndrome (BBS) | Recruiting | 2023-01-01 | 2030-12-31 | ClinicalTrials.gov |
| NCT05398991 | Coronary Covered Stents Implantation for the Treatment of Coronary Artery Perfo… | Na | Coronary Artery Perforation | Unknown | 2022-10-26 | 2025-07-01 | ClinicalTrials.gov |
| NCT05510167 | Post-ablation Alcohol Impacts Arrhythmia Recurrence, Quality of Life and Cognit… | Na | Atrial Fibrillation | Unknown | 2022-08-22 | 2025-08-01 | ClinicalTrials.gov |
| NCT05447585 | Coronary Atherectomy System in Patients With Coronary Calcification (CORECT) | Na | Calcification of Coronary Artery | Unknown | 2022-07-01 | 2024-12-10 | ClinicalTrials.gov |
| NCT05357729 | Safety and Performance Study of the MultiSense® Ambulatory Telemonitoring Syste… | Na | Visceral and Digestive Surgery | Completed | 2022-06-14 | 2022-09-02 | ClinicalTrials.gov |
| NCT06060548 | Role of Novel ILR in the Management of PVCs | — | PVC - Premature Ventricular Contraction | Recruiting | 2022-04-20 | 2025-12-01 | ClinicalTrials.gov |
| NCT05466942 | RDS MultiSense® SpO2 Calibration | Na | Hypoxia | Completed | 2022-03-15 | 2022-10-20 | ClinicalTrials.gov |
| NCT05086679 | Compression Stockings for Treating Vasovagal Syncope Trial | Na | Syncope, Vasovagal | Unknown | 2022-03-14 | 2024-12-10 | ClinicalTrials.gov |
| NCT04577859 | Esophageal Protection Study: A Multicenter Study | Na | AF - Atrial Fibrillation | Completed | 2022-03-10 | 2026-05-15 | ClinicalTrials.gov |
| NCT04966741 | Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity | Phase3 | Bardet-Biedl Syndrome | Completed | 2022-03-08 | 2024-11-08 | ClinicalTrials.gov |
| NCT05229848 | ICE Based Atrial Flutter Ablation Vs Conventional Fluoroscopy/Anatomical Mappin… | Na | Atrial Flutter | Unknown | 2022-02-01 | 2022-04-01 | ClinicalTrials.gov |
| NCT05242250 | Real-World Evidence Registry to Assess Outcomes of Catheter Ablation for Atrial… | — | Atrial Fibrillation | Terminated | 2022-01-10 | 2023-12-31 | ClinicalTrials.gov |
| NCT05194124 | Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants Wi… | Phase3 | Bardet-Biedl Syndrome | Completed | 2021-12-21 | 2023-10-19 | ClinicalTrials.gov |
| NCT05093634 | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in th… | Phase3 | Obesity | Active_Not_Recruiting | 2021-12-10 | 2026-12-31 | ClinicalTrials.gov |
| NCT04442113 | RandOmised Controlled Trial of STAR Mapping™ Guided Ablation for AF. | Na | Atrial Fibrillation | Withdrawn | 2021-12-01 | 2022-09-01 | ClinicalTrials.gov |
| NCT04963231 | DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants … | Phase2 | Genetic Obesity | Completed | 2021-11-30 | 2024-09-30 | ClinicalTrials.gov |
| NCT04689256 | Pilot Randomized Controlled Study of the Impact of MedRhythms' MR-010 in Acute … | Na | Stroke, Acute | Terminated | 2021-11-03 | 2023-01-30 | ClinicalTrials.gov |
| NCT04637230 | Prevention of Stroke and Sudden Cardiac Death by Recording of 1-Channel Electro… | — | Sinus Rhythm | Unknown | 2021-10-01 | 2023-06-30 | ClinicalTrials.gov |
| NCT04661423 | Use of RDS MultiSense® in Post-ICU Patients in the COVID-19 Era | Na | Post ICU Rehabilitation | Completed | 2021-09-02 | 2025-03-02 | ClinicalTrials.gov |
| NCT05046132 | Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Partic… | Phase4 | Healthy | Completed | 2021-08-05 | 2022-04-07 | ClinicalTrials.gov |
| NCT04725240 | Open-Label Study of Setmelanotide in Hypothalamic Obesity | Phase2 | Hypothalamic Obesity | Completed | 2021-06-07 | 2022-06-28 | ClinicalTrials.gov |
| NCT04505163 | Left Atrial Posterior Wall and PV Isolation Using Cryoballoon for Treatment of … | Na | Persistent Atrial Fibrillation | Unknown | 2021-04-30 | 2024-12-31 | ClinicalTrials.gov |
| NCT04830774 | Natural History of COVID-19-Related Atrial Fibrillation | Na | COVID-19 | Unknown | 2021-04-15 | 2023-12-31 | ClinicalTrials.gov |
| NCT04895540 | South Asian Arrhythmogenic Cardiomyopathy Registry | — | Arrhythmogenic Right Ventricular Cardiomyopathy | Unknown | 2021-04-10 | 2022-05-01 | ClinicalTrials.gov |
| NCT04445493 | EPISODE-PS-COVID: hEad Pulse for Ischemic StrOke DEtection Prehospital Study Du… | — | Stroke, Acute | Completed | 2021-03-01 | 2023-01-01 | ClinicalTrials.gov |
| NCT04493970 | HS Students Mandatory Universal Student Instruction in CPR Appraised Learning- … | — | Sudden Cardiac Arrest | Recruiting | 2021-02-26 | 2024-10-01 | ClinicalTrials.gov |
| NCT04726943 | RF Applications for Residual LAA Leaks | Na | Left Atrial Appendage Thrombosis | Unknown | 2021-02-01 | 2022-12-31 | ClinicalTrials.gov |
| NCT04499807 | Accuracy of Rhythm Detection by a Wearable Smart Watch for Cardiac Arrhythmias … | Na | Atrial Fibrillation | Terminated | 2021-01-06 | 2021-03-16 | ClinicalTrials.gov |
| NCT04473807 | Feasibility and Safety of IV Sotalol Administered as a Loading Dose to Initiate… | Phase4 | Arrhythmias, Cardiac | Unknown | 2021-01-02 | 2022-06-01 | ClinicalTrials.gov |
| NCT04480385 | REmote Data Acquisition After SURgery | Na | Visceral and Digestive Surgery | Completed | 2020-12-07 | 2022-05-20 | ClinicalTrials.gov |
| NCT04595942 | Midodrine and Fludrocortisone for Vasovagal Syncope | Phase3 | Syncope, Vasovagal | Unknown | 2020-11-19 | 2023-12-01 | ClinicalTrials.gov |
| NCT04599114 | Virtual for Care Atrial Fibrillation Patients Using VIRTUES | Na | Atrial Fibrillation | Unknown | 2020-11-01 | 2024-11-01 | ClinicalTrials.gov |
| NCT03636230 | Virtual E-health System for Pacemakers | Na | Pacemaker | Active_Not_Recruiting | 2020-09-15 | 2026-06-30 | ClinicalTrials.gov |
| NCT04420182 | COVID-19 Virtual Care at Home | Na | Covid-19 | Completed | 2020-08-17 | 2022-02-04 | ClinicalTrials.gov |
| NCT04476524 | Clinical and Economic Impact of an Organized Treatment Pathway on AFib Patient … | — | Cardiac Arrhythmia | Unknown | 2020-08-15 | 2021-12-01 | ClinicalTrials.gov |
| NCT04502017 | Efficacy of Different Anti-Thrombotic Strategies on Device-Related Thrombosis P… | Phase4 | Device-Related Thrombosis | Unknown | 2020-08-05 | 2023-12-31 | ClinicalTrials.gov |
| NCT04465552 | Arrhythmic Manifestations and Management in Hospitalized COVID-19 Patients | — | Coronavirus Infections | Completed | 2020-07-10 | 2021-01-24 | ClinicalTrials.gov |
| NCT04348175 | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects W… | Phase1 | Renal Insufficiency | Completed | 2020-07-09 | 2021-04-17 | ClinicalTrials.gov |
| NCT04314076 | Rhythmic Auditory Stimulation & Gait Training | Na | Multiple Sclerosis | Completed | 2020-06-08 | 2022-11-07 | ClinicalTrials.gov |
| NCT04371926 | Prophylactic Benefit of Hydroxychloroquine in COVID-19 Cases With Mild to Moder… | Na | COVID-19 | Withdrawn | 2020-06-01 | 2021-07-01 | ClinicalTrials.gov |
| NCT03405740 | Virtual E-health System for Implantable Cardioverter Defibrillators | Na | Cardiac Arrhythmia | Active_Not_Recruiting | 2020-05-01 | 2026-06-30 | ClinicalTrials.gov |
| NCT04352764 | ANTIBODY BASED TESTS FOR SARSCoV-2 COVID-19) - Evaluation of Patients and Healt… | — | Covid19 | Unknown | 2020-03-27 | 2021-01-31 | ClinicalTrials.gov |
| NCT04037397 | First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Persistent A… | Phase3 | Atrial Fibrillation | Completed | 2019-09-24 | 2024-10-01 | ClinicalTrials.gov |
| NCT04121754 | Post-Stroke Walking Speed and Community Ambulation Conversion Study | Na | Chronic Stroke | Completed | 2019-09-17 | 2022-02-11 | ClinicalTrials.gov |
| NCT03621007 | An Observational,Prospective Natural History Study of Early-Onset Extreme Obesi… | — | POMC Deficiency Obesity | Completed | 2019-08-06 | 2021-01-22 | ClinicalTrials.gov |
| NCT03682991 | Reversal of Atrial Substrate to Prevent Atrial | Na | Atrial Fibrillation | Active_Not_Recruiting | 2019-07-01 | 2027-12-31 | ClinicalTrials.gov |
| NCT04222868 | Indonesian Registry on Atrial Fibrillation | — | Atrial Fibrillation | Unknown | 2019-01-01 | 2021-12-30 | ClinicalTrials.gov |
| NCT04302311 | Early Diagnosis of Atrial Fibrillation in the Wait-Time Prior to Seeing a Cardi… | Na | Atrial Fibrillation | Unknown | 2018-12-18 | 2024-03-01 | ClinicalTrials.gov |
| NCT03746522 | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl… | Phase3 | Bardet Biedl Syndrome (BBS) | Completed | 2018-11-23 | 2021-03-08 | ClinicalTrials.gov |
| NCT03627143 | Decreasing Hospital Admissions From the ED for AAFF | Na | Atrial Fibrillation | Completed | 2018-09-01 | 2019-10-30 | ClinicalTrials.gov |
| NCT03651765 | Long Term Extension Trial of Setmelanotide | Phase2 | Obesity Associated With Defects in Leptin-melanocortin Pathway | Completed | 2018-07-15 | 2025-01-09 | ClinicalTrials.gov |
| NCT03080857 | Computer Simulated Atrial Fibrillation Tool | Na | Atrial Fibrillation | Completed | 2018-05-15 | 2020-05-31 | ClinicalTrials.gov |
| NCT03498586 | Half-normal Saline in Atrial Fibrillation Ablation | Na | Atrial Fibrillation | Completed | 2018-05-02 | 2020-05-02 | ClinicalTrials.gov |
| NCT03467633 | Atrial Fibrillation Trial to Evade Recurrence: effectS of Hiit Before electrO-C… | Na | Persistent Atrial Fibrillation | Terminated | 2018-04-25 | 2020-10-08 | ClinicalTrials.gov |
| NCT03479437 | The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry | — | Genetic Forms of Extreme Obesity | Completed | 2018-04-15 | 2020-12-01 | ClinicalTrials.gov |
| NCT03503253 | Transcatheter Leak Closure With Detachable Coils Following Incomplete Left Atri… | Na | Left Atrial Appendage Incomplete Closure | Unknown | 2018-04-09 | 2022-05-01 | ClinicalTrials.gov |
| NCT03287960 | Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity | Phase3 | Leptin Receptor Deficiency Obesity | Completed | 2018-01-30 | 2020-09-25 | ClinicalTrials.gov |
| NCT06352060 | Dynamic Data-Driven Management of Atrial Fibrillation Using Implantable Cardiac… | — | Atrial Fibrillation | Completed | 2018-01-01 | 2021-12-31 | ClinicalTrials.gov |
| NCT04088071 | Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | — | Paroxysmal Atrial Fibrillation | Recruiting | 2018-01-01 | 2028-12-31 | ClinicalTrials.gov |
| NCT03440762 | Atrial Fibrillation Screening and Education Study | Na | Atrial Fibrillation | Completed | 2017-08-16 | 2019-08-27 | ClinicalTrials.gov |
| NCT03262610 | Setmelanotide in a Single Patient With Partial Lipodystrophy | Phase2 | Hypertriglyceridemia | Completed | 2017-08-15 | 2018-01-31 | ClinicalTrials.gov |
| NCT03127085 | A.Fib Emergency Department Study Atrial Fibrillation | — | Atrial Fibrillation | Completed | 2017-04-21 | 2018-09-27 | ClinicalTrials.gov |
| NCT02666742 | DOACs for Stroke Prevention Post Ventricular Tachycardia Ablation | Phase4 | Ventricular Tachycardia | Completed | 2017-02-16 | 2021-04-30 | ClinicalTrials.gov |
| NCT02896192 | Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Defi… | Phase3 | Pro-opiomelanocortin (POMC) Deficiency Obesity | Completed | 2017-02-14 | 2020-05-25 | ClinicalTrials.gov |
| NCT03013543 | Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorde… | Phase2 | Genetic Obesity | Completed | 2017-02-10 | 2022-03-01 | ClinicalTrials.gov |
| NCT03501836 | Wireless Handheld 8-lead ECG Device Performance in Heart Patients (Rapid Rhythm) | Na | Atrial Fibrillation | Completed | 2017-01-24 | 2019-06-30 | ClinicalTrials.gov |
| NCT03035227 | Catheter Ablation of Arrhythmias to Improve CRT Response | Phase4 | Arrhythmia, Cardiac | Terminated | 2017-01-23 | 2018-05-01 | ClinicalTrials.gov |
| NCT02830360 | Antiarrhythmics or Ablation for Ventricular Tachycardia 2 | Phase4 | Ventricular Tachycardia (VT) | Completed | 2016-10-01 | 2024-06-30 | ClinicalTrials.gov |
| NCT02585817 | Remote Patient Management for Cardiac Implantable Electronic Devices | Na | Arrhythmia, Cardiac | Completed | 2016-10-01 | 2019-04-01 | ClinicalTrials.gov |
| NCT02849977 | Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and… | — | Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations | Completed | 2016-09-28 | 2020-06-09 | ClinicalTrials.gov |
| NCT02781779 | Comparison of Outcomes Between the Use of Silverlon® Dressing and AQUACEL® AG D… | Na | Infections | Completed | 2016-06-01 | 2017-12-01 | ClinicalTrials.gov |
| NCT04807049 | Clinical Survey on the Stroke Prevention in Atrial Fibrillation in Asia | — | Atrial Fibrillation | Completed | 2016-04-01 | 2021-03-01 | ClinicalTrials.gov |
| NCT02547584 | Impact of Anxiety on Cardiac Substrate Modification in Women With Atrial Fibril… | Na | Atrial Fibrillation | Unknown | 2015-09-01 | 2022-07-01 | ClinicalTrials.gov |
| NCT02500732 | Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope | Phase2 | Vasovagal Syncope | Completed | 2015-07-01 | 2018-03-01 | ClinicalTrials.gov |
| NCT02311673 | Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obes… | Phase2 | Prader-Willi Syndrome | Completed | 2015-03-19 | 2016-10-26 | ClinicalTrials.gov |
| NCT05131308 | Multimodality Evaluation of LAA Leaks Arising After Incomplete LAAC: Insights F… | — | Left Atrail Appendage Closure: Peri-device Leaks | Completed | 2015-01-11 | 2021-06-08 | ClinicalTrials.gov |
| NCT02219841 | Impact of Life-Style Modification On Ablation Outcome in Atrial Fibrillation | — | Atrial Fibrillation | Unknown | 2014-08-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT02208102 | Role of Cardiac Biomarkers in Prediction of Outcome in Atrial Fibrillation Pati… | — | Atrial Fibrillation | Completed | 2014-07-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT01816308 | Cognitive Impairment in Atrial Fibrillation | — | Atrial Fibrillation | Unknown | 2014-07-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT02533843 | Outcome of Different Ablation Strategies In Persistent and Long-Standing Persis… | Phase3 | Atrial Fibrillation | Completed | 2014-04-01 | 2017-07-01 | ClinicalTrials.gov |
| NCT02041195 | Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Pat… | Phase1 | Overweight and Obesity | Completed | 2014-01-01 | 2014-12-01 | ClinicalTrials.gov |
| NCT01672346 | PV Reconnection After PVAI at Different Power Settings and Adenosine Provocation | Phase3 | Paroxysmal Atrial Fibrillation | Unknown | 2013-05-01 | 2020-12-01 | ClinicalTrials.gov |
| NCT01867437 | Effects of RM-493 on Energy Expenditure in Obese Individuals | Phase1 | Obesity | Completed | 2013-05-01 | 2014-03-01 | ClinicalTrials.gov |
| NCT01749137 | Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants | Phase2 | Overweight | Completed | 2013-01-14 | 2013-09-28 | ClinicalTrials.gov |
| NCT01849705 | Melanocortin 4 Receptor Mutations and Obesity-associated Diseases | — | Obesity | Completed | 2012-10-01 | 2013-02-01 | ClinicalTrials.gov |
| NCT01660100 | Outcome of Atrial Fibrillation Ablation After Permanent Pulmonary Vein Antrum I… | Na | Atrial Fibrillation | Completed | 2012-07-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT01695564 | Safety and Efficacy of Left Atrial Appendage Occlusion Devices | — | Atrial Fibrillation | Completed | 2012-05-01 | 2018-02-01 | ClinicalTrials.gov |
| NCT01696344 | Does Atrial Fibrillation (AF) Termination Without Additional Ablation Influence… | — | Atrial Fibrillation | Unknown | 2012-05-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT02431442 | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics o… | Phase1 | Overweight | Completed | 2012-01-01 | 2014-01-01 | ClinicalTrials.gov |
| NCT01439386 | Impact Of Different Ablation Approaches on Outcome In Coexistent Atrial Fibrill… | Phase3 | Atrial Arrhythmia | Completed | 2011-09-01 | 2016-07-01 | ClinicalTrials.gov |
| NCT01391091 | Effect of Catheter Ablation on Clinical Course of Migraine in AF Patients With … | Phase3 | Migraine | Completed | 2010-12-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01362738 | Effect of Empirical Left Atrial Appendage Isolation on Long-term Procedure Outc… | Phase3 | Persistent Atrial Fibrillation | Completed | 2010-11-01 | 2016-11-01 | ClinicalTrials.gov |
| NCT01173809 | Effect of Amiodarone on the Procedure Outcome in Long-standing Persistent Atria… | Phase3 | Atrial Fibrillation | Completed | 2010-10-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01173796 | Ablation of Perimitral Flutter Following Catheter Ablation of Atrial Fibrillati… | Phase3 | Atrial Fibrillation | Completed | 2010-03-01 | 2011-09-01 | ClinicalTrials.gov |
| NCT01006876 | Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Pati… | Phase3 | Thromboembolism | Completed | 2010-01-01 | 2014-04-01 | ClinicalTrials.gov |
| NCT01892774 | Impact of the Pulmonary Vein Isolation on Exercise Capacity in Patients With Ch… | — | Chronic Atrial Fibrillation | Unknown | 2010-01-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT01045668 | Ablation of Clinical Ventricular Tachycardia Versus Addition of Substrate Ablat… | Phase3 | Ventricular Tachycardia | Completed | 2010-01-01 | 2014-07-01 | ClinicalTrials.gov |
| NCT01378572 | Electrophysiologic and Morphologic Assessment of the Substrate to Guide Implant… | — | Dilated Cardiomyopathy | Unknown | 2009-11-01 | — | ClinicalTrials.gov |
| NCT00729911 | Ablation vs Amiodarone for Treatment of AFib in Patients With CHF and an ICD | Phase4 | Heart Failure | Completed | 2008-10-01 | 2015-12-01 | ClinicalTrials.gov |
| NCT00392106 | High Intensity Focused Ultrasound (HIFU) Ablation System Study | Phase3 | Atrial Fibrillation | Suspended | 2006-04-01 | 2011-06-01 | ClinicalTrials.gov |
Total clinical trials: 154
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Catheter ablation | Other | Preclinical | Paroxysmal Atrial Fibrillation | RECRUITING | NCT04088071 |
| Esophageal temperature monitoring probe | Other | Approved | AF - Atrial Fibrillation | COMPLETED | NCT04577859 |
| ensoETM. Esophageal cooling during AF ablation | Other | Approved | AF - Atrial Fibrillation | COMPLETED | NCT04577859 |
| MR-C-014 | Other | Approved | Neuromyelitis Optica Spectrum Disorder | ENROLLING_BY_INVITATION | NCT06374264 |
| Setmelanotide | Other | Phase PHASE4 | Bardet Biedl Syndrome (BBS) | RECRUITING | NCT07674290 |
| BodyGuardian | Other | Preclinical | Atrial Fibrillation (AF) | NOT_YET_RECRUITING | NCT07671677 |
| Placebo | Other | Phase PHASE3 | Hypothalamic Obesity | ACTIVE_NOT_RECRUITING | NCT05774756 |
| Setmelanotide | Other | Phase PHASE3 | Hypothalamic Obesity | ACTIVE_NOT_RECRUITING | NCT05774756 |
| Pulsed Field Ablation | Other | Preclinical | Atrial Fibrillation | ENROLLING_BY_INVITATION | NCT06335082 |
| Arrhythmia Mapping | Other | Preclinical | Arrhythmias, Cardiac | COMPLETED | NCT06939478 |
| Pulsed Field Ablation | Other | Preclinical | Atrial Fibrillation | ENROLLING_BY_INVITATION | NCT06335082 |
| Arrhythmia Mapping | Other | Preclinical | Arrhythmias, Cardiac | COMPLETED | NCT06939478 |
| Pulsed Field Ablation | Other | Preclinical | Atrial Fibrillation | ENROLLING_BY_INVITATION | NCT06335082 |
| Arrhythmia Mapping | Other | Preclinical | Arrhythmias, Cardiac | COMPLETED | NCT06939478 |
| Pulsed Field Ablation | Other | Preclinical | Atrial Fibrillation | ENROLLING_BY_INVITATION | NCT06335082 |
| Arrhythmia Mapping | Other | Preclinical | Arrhythmias, Cardiac | COMPLETED | NCT06939478 |
| Pulsed Field Ablation | Other | Preclinical | Atrial Fibrillation | ENROLLING_BY_INVITATION | NCT06335082 |
| Arrhythmia Mapping | Other | Preclinical | Arrhythmias, Cardiac | COMPLETED | NCT06939478 |
| Standard of care | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Standard of care | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Standard of care | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Standard of care | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Standard of care | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Standard of care | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Standard of care | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Standard of care | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | ACTIVE_NOT_RECRUITING | NCT03636230 |
| Standard of Care | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Remote Patient Management | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Standard of Care | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Remote Patient Management | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Standard of Care | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Remote Patient Management | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Standard of Care | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Remote Patient Management | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Standard of Care | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Remote Patient Management | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Standard of Care | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Remote Patient Management | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Coumadin | Other | Phase PHASE3 | Thromboembolism | COMPLETED | NCT01006876 |
| Coumadin | Other | Phase PHASE3 | Thromboembolism | COMPLETED | NCT01006876 |
| Zio monitor | Other | Approved | Syncope | COMPLETED | NCT07118124 |
| Zio monitor | Other | Approved | Syncope | COMPLETED | NCT07118124 |
| Zio monitor | Other | Approved | Syncope | COMPLETED | NCT07118124 |
| Zio monitor | Other | Approved | Syncope | COMPLETED | NCT07118124 |
| Zio monitor | Other | Approved | Syncope | COMPLETED | NCT07118124 |
| Zio monitor | Other | Approved | Syncope | COMPLETED | NCT07118124 |
| Zio monitor | Other | Approved | Syncope | COMPLETED | NCT07118124 |
| Zio monitor | Other | Approved | Syncope | COMPLETED | NCT07118124 |
| Lifestyle modification | Other | Approved | Syncope, Vasovagal | UNKNOWN | NCT05086679 |
| Compression stockings with up to <=10 mm Hg pressure | Other | Approved | Syncope, Vasovagal | UNKNOWN | NCT05086679 |
| Compression Stockings with 25-30 mm Hg pressure | Other | Approved | Syncope, Vasovagal | UNKNOWN | NCT05086679 |
| Catheter ablation | Other | Phase PHASE3 | Atrial Arrhythmia | COMPLETED | NCT01439386 |
| Catheter ablation | Other | Phase PHASE3 | Atrial Arrhythmia | COMPLETED | NCT01439386 |
| Amiodarone | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT00729911 |
| Atrial Fibrillation ablation | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT00729911 |
| Amiodarone | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT00729911 |
| Atrial Fibrillation ablation | Other | Phase PHASE4 | Heart Failure | COMPLETED | NCT00729911 |
| Catheter ablation | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT02547584 |
| Catheter ablation | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT02547584 |
| AliveCor Heart Monitor | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03080857 |
| Virtual Platform | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03080857 |
| AliveCor Heart Monitor | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03080857 |
| Virtual Platform | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03080857 |
| Normal saline | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03498586 |
| Half-normal saline | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03498586 |
| Normal saline | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03498586 |
| Half-normal saline | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03498586 |
| Lifestyle modification | Other | Approved | Syncope, Vasovagal | UNKNOWN | NCT05086679 |
| Compression stockings with up to <=10 mm Hg pressure | Other | Approved | Syncope, Vasovagal | UNKNOWN | NCT05086679 |
| Compression Stockings with 25-30 mm Hg pressure | Other | Approved | Syncope, Vasovagal | UNKNOWN | NCT05086679 |
| NSE Coronary Dilatation Catheter | Other | Approved | Coronary Artery Stenosis | UNKNOWN | NCT05606367 |
| Non-slip Balloon Catheter of Shanghai MicroPort Rhythm | Other | Approved | Coronary Artery Stenosis | UNKNOWN | NCT05606367 |
| High School Students Survey | Other | Preclinical | Sudden Cardiac Arrest | RECRUITING | NCT04493970 |
| High School Students Survey | Other | Preclinical | Sudden Cardiac Arrest | RECRUITING | NCT04493970 |
| Catheter ablation | Other | Preclinical | Paroxysmal Atrial Fibrillation | RECRUITING | NCT04088071 |
| Catheter ablation | Other | Preclinical | Paroxysmal Atrial Fibrillation | RECRUITING | NCT04088071 |
| Amiodarone | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| Pulmonary vein ablation | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| sotolol | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| dofetilide | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| flecainide | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| propafenone | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| Amiodarone | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| Pulmonary vein ablation | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| sotolol | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| dofetilide | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| flecainide | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| propafenone | Other | Phase PHASE3 | Atrial Fibrillation | SUSPENDED | NCT00392106 |
| catheter ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT01173796 |
| catheter ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT01173796 |
| No intervention | Other | Preclinical | Obesity | COMPLETED | NCT01849705 |
| Amiodarone | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT01173809 |
| Amiodarone | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT01173809 |
| Radiofrequency Catheter Ablation (RFCA) | Other | Phase PHASE3 | Ventricular Tachycardia | COMPLETED | NCT01045668 |
| Radiofrequency Catheter Ablation (RFCA) | Other | Phase PHASE3 | Ventricular Tachycardia | COMPLETED | NCT01045668 |
| Placebo | Other | Phase PHASE1 | Overweight | COMPLETED | NCT02431442 |
| RM-493 | Other | Phase PHASE1 | Overweight | COMPLETED | NCT02431442 |
| Radiofrequency catheter ablation | Other | Phase PHASE3 | Migraine | COMPLETED | NCT01391091 |
| Radiofrequency catheter ablation | Other | Phase PHASE3 | Migraine | COMPLETED | NCT01391091 |
| RM-493 | Other | Phase PHASE1 | Obesity | COMPLETED | NCT01867437 |
| Placebo | Other | Phase PHASE1 | Obesity | COMPLETED | NCT01867437 |
| LAA isolation along with the conventional ablation strategy | Other | Phase PHASE3 | Persistent Atrial Fibrillation | COMPLETED | NCT01362738 |
| RFCA of PV and extra-PV triggers | Other | Phase PHASE3 | Persistent Atrial Fibrillation | COMPLETED | NCT01362738 |
| LAA isolation along with the conventional ablation strategy | Other | Phase PHASE3 | Persistent Atrial Fibrillation | COMPLETED | NCT01362738 |
| RFCA of PV and extra-PV triggers | Other | Phase PHASE3 | Persistent Atrial Fibrillation | COMPLETED | NCT01362738 |
| Radio-frequency catheter ablation | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT02208102 |
| Radio-frequency catheter ablation | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT02208102 |
| PVAI plus left atrial posterior wall (LAPW) isolation | Other | Approved | Atrial Fibrillation | COMPLETED | NCT01660100 |
| Pulmonary vein antrum isolation (PVAI) | Other | Approved | Atrial Fibrillation | COMPLETED | NCT01660100 |
| PVAI plus left atrial posterior wall (LAPW) isolation | Other | Approved | Atrial Fibrillation | COMPLETED | NCT01660100 |
| Pulmonary vein antrum isolation (PVAI) | Other | Approved | Atrial Fibrillation | COMPLETED | NCT01660100 |
| radiofrequency catheter ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT02533843 |
| radiofrequency catheter ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT02533843 |
| radiofrequency catheter ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT02533843 |
| Radiofrequency catheter ablation | Other | Preclinical | Chronic Atrial Fibrillation | UNKNOWN | NCT01892774 |
| Radiofrequency catheter ablation | Other | Preclinical | Chronic Atrial Fibrillation | UNKNOWN | NCT01892774 |
| Radiofrequency catheter ablation | Other | Preclinical | Chronic Atrial Fibrillation | UNKNOWN | NCT01892774 |
| PVAI + ablation of extraPV triggers | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT01696344 |
| PVAI | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT01696344 |
| PVAI + ablation of extraPV triggers | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT01696344 |
| PVAI | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT01696344 |
| PVAI + ablation of extraPV triggers | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT01696344 |
| PVAI | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT01696344 |
| PVAI followed by adenosine provocation | Other | Phase PHASE3 | Paroxysmal Atrial Fibrillation | UNKNOWN | NCT01672346 |
| PVAI followed by adenosine provocation | Other | Phase PHASE3 | Paroxysmal Atrial Fibrillation | UNKNOWN | NCT01672346 |
| Remote CIED Management | Other | Approved | Arrhythmia, Cardiac | COMPLETED | NCT02585817 |
| WATCHMAN | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT01695564 |
| LARIAT LAA | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT01695564 |
| WATCHMAN | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT01695564 |
| LARIAT LAA | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT01695564 |
| radiofrequency catheter ablation | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT02219841 |
| radiofrequency catheter ablation | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT02219841 |
| Placebo | Other | Phase PHASE2 | Vasovagal Syncope | COMPLETED | NCT02500732 |
| Atomoxetine | Other | Phase PHASE2 | Vasovagal Syncope | COMPLETED | NCT02500732 |
| Placebo | Other | Phase PHASE2 | Vasovagal Syncope | COMPLETED | NCT02500732 |
| Atomoxetine | Other | Phase PHASE2 | Vasovagal Syncope | COMPLETED | NCT02500732 |
| CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test | Other | Preclinical | Covid19 | UNKNOWN | NCT04352764 |
| CoronaCideTM COVID-19 IgM/IgG Rapid Test and Premier Biotech COVID-19 IgM/IgG Rapid Test | Other | Preclinical | Covid19 | UNKNOWN | NCT04352764 |
| Hydroxychloroquine Sulfate | Other | Approved | COVID-19 | WITHDRAWN | NCT04371926 |
| Hydroxychloroquine Sulfate | Other | Approved | COVID-19 | WITHDRAWN | NCT04371926 |
| Half-Dose of novel OAC | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| Genetic-Tailored AntiThrombotic Strategy | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| ASA plus Clopidogrel | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| Half-Dose of novel OAC | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| Genetic-Tailored AntiThrombotic Strategy | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| ASA plus Clopidogrel | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| Half-Dose of novel OAC | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| Genetic-Tailored AntiThrombotic Strategy | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| ASA plus Clopidogrel | Other | Phase PHASE4 | Device-Related Thrombosis | UNKNOWN | NCT04502017 |
| AF awareness education | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03440762 |
| AF awareness education | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03440762 |
| AF awareness education | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03440762 |
| VIRTUES | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT04599114 |
| VIRTUES | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT04599114 |
| High-intensity interval training | Other | Approved | Persistent Atrial Fibrillation | TERMINATED | NCT03467633 |
| Quality improvement | Other | Preclinical | Cardiac Arrhythmia | UNKNOWN | NCT04476524 |
| Quality improvement | Other | Preclinical | Cardiac Arrhythmia | UNKNOWN | NCT04476524 |
| Radiofrequency Energy Applications | Other | Approved | Left Atrial Appendage Thrombosis | UNKNOWN | NCT04726943 |
| Radiofrequency Energy Applications | Other | Approved | Left Atrial Appendage Thrombosis | UNKNOWN | NCT04726943 |
| Radiofrequency Energy Applications | Other | Approved | Left Atrial Appendage Thrombosis | UNKNOWN | NCT04726943 |
| Observational | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT04807049 |
| Observational | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT04807049 |
| Observational | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT04807049 |
| Azur Peripheral Coil System | Other | Approved | Left Atrial Appendage Incomplete Closure | UNKNOWN | NCT03503253 |
| Concerto Helix Detachable Coil System | Other | Approved | Left Atrial Appendage Incomplete Closure | UNKNOWN | NCT03503253 |
| Interlock-35 Fibered IDC Occlusion System | Other | Approved | Left Atrial Appendage Incomplete Closure | UNKNOWN | NCT03503253 |
| Azur Peripheral Coil System | Other | Approved | Left Atrial Appendage Incomplete Closure | UNKNOWN | NCT03503253 |
| Concerto Helix Detachable Coil System | Other | Approved | Left Atrial Appendage Incomplete Closure | UNKNOWN | NCT03503253 |
| Interlock-35 Fibered IDC Occlusion System | Other | Approved | Left Atrial Appendage Incomplete Closure | UNKNOWN | NCT03503253 |
| Pulmonary vein isolation | Other | Approved | Atrial Fibrillation | WITHDRAWN | NCT04442113 |
| Pulmonary vein isolation plus ablation guided by novel STAR mapping™ | Other | Approved | Atrial Fibrillation | WITHDRAWN | NCT04442113 |
| Pulmonary vein isolation | Other | Approved | Atrial Fibrillation | WITHDRAWN | NCT04442113 |
| Pulmonary vein isolation plus ablation guided by novel STAR mapping™ | Other | Approved | Atrial Fibrillation | WITHDRAWN | NCT04442113 |
| Lifestyle modification | Other | Phase PHASE3 | Syncope, Vasovagal | UNKNOWN | NCT04595942 |
| Fludrocortisone Acetate Tablets | Other | Phase PHASE3 | Syncope, Vasovagal | UNKNOWN | NCT04595942 |
| Midodrine Hydrochloride Tablets | Other | Phase PHASE3 | Syncope, Vasovagal | UNKNOWN | NCT04595942 |
| Lifestyle modification | Other | Phase PHASE3 | Syncope, Vasovagal | UNKNOWN | NCT04595942 |
| Fludrocortisone Acetate Tablets | Other | Phase PHASE3 | Syncope, Vasovagal | UNKNOWN | NCT04595942 |
| Midodrine Hydrochloride Tablets | Other | Phase PHASE3 | Syncope, Vasovagal | UNKNOWN | NCT04595942 |
| All study subjects will undergo sample collection for genetic testing. | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| Cardiac EP study | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| Ambulatory ECG recording | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| Cardiac MRI | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| Echocardiography | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| ECG | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| All study subjects will undergo sample collection for genetic testing. | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| Cardiac EP study | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| Ambulatory ECG recording | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| Cardiac MRI | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| Echocardiography | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| ECG | Other | Preclinical | Arrhythmogenic Right Ventricular Cardiomyopathy | UNKNOWN | NCT04895540 |
| KTI activities | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03627143 |
| KTI activities | Other | Approved | Atrial Fibrillation | COMPLETED | NCT03627143 |
| Setmelanotide | Other | Phase PHASE1 | Renal Insufficiency | COMPLETED | NCT04348175 |
| Patients received standard of care treatment during hospitalization | Drug | Preclinical | Coronavirus Infections | COMPLETED | NCT04465552 |
| Patients received standard of care treatment during hospitalization | Drug | Preclinical | Coronavirus Infections | COMPLETED | NCT04465552 |
| ILR, PMK, ICD | Other | Approved | COVID-19 | UNKNOWN | NCT04830774 |
| ILR, PMK, ICD | Other | Approved | COVID-19 | UNKNOWN | NCT04830774 |
| Setmelanotide | Other | Phase PHASE2 | Hypertriglyceridemia | COMPLETED | NCT03262610 |
| Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation | Drug | Phase PHASE4 | Arrhythmias, Cardiac | UNKNOWN | NCT04473807 |
| Intravenous Sotalol Administered as a Loading Dose to Initiate Oral Sotalol Therapy in Adult Patients with Atrial Fibrillation | Drug | Phase PHASE4 | Arrhythmias, Cardiac | UNKNOWN | NCT04473807 |
| ICE plus 3D electroanatomical mapping guided CTI ablation | Other | Approved | Atrial Flutter | UNKNOWN | NCT05229848 |
| 3D electroanatomical mapping alone guided CTI ablation | Other | Approved | Atrial Flutter | UNKNOWN | NCT05229848 |
| ICE plus 3D electroanatomical mapping guided CTI ablation | Other | Approved | Atrial Flutter | UNKNOWN | NCT05229848 |
| 3D electroanatomical mapping alone guided CTI ablation | Other | Approved | Atrial Flutter | UNKNOWN | NCT05229848 |
| Electrocardiogram analysis by Artificial Intelligence | Other | Preclinical | Sinus Rhythm | UNKNOWN | NCT04637230 |
| Electrocardiogram analysis by Artificial Intelligence | Other | Preclinical | Sinus Rhythm | UNKNOWN | NCT04637230 |
| Virtual Care at Home | Other | Approved | Covid-19 | COMPLETED | NCT04420182 |
| Virtual Care at Home | Other | Approved | Covid-19 | COMPLETED | NCT04420182 |
| Virtual Care at Home | Other | Approved | Covid-19 | COMPLETED | NCT04420182 |
| Rotablator Rotational Atherectomy System | Other | Approved | Calcification of Coronary Artery | UNKNOWN | NCT05447585 |
| Coronary atherectomy system of Shanghai MicroPort Rhythm | Other | Approved | Calcification of Coronary Artery | UNKNOWN | NCT05447585 |
| Rotablator Rotational Atherectomy System | Other | Approved | Calcification of Coronary Artery | UNKNOWN | NCT05447585 |
| Coronary atherectomy system of Shanghai MicroPort Rhythm | Other | Approved | Calcification of Coronary Artery | UNKNOWN | NCT05447585 |
| Setmelanotide, administered subcutaneously [SC], once daily. | Other | Preclinical | Bardet-Biedl Syndrome (BBS) | APPROVED_FOR_MARKETING | NCT05183802 |
| Study arm | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT05510167 |
| Study arm | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT05510167 |
| Aspirin | Other | Phase PHASE4 | Ventricular Tachycardia | COMPLETED | NCT02666742 |
| DOAC | Other | Phase PHASE4 | Ventricular Tachycardia | COMPLETED | NCT02666742 |
| Aspirin | Other | Phase PHASE4 | Ventricular Tachycardia | COMPLETED | NCT02666742 |
| DOAC | Other | Phase PHASE4 | Ventricular Tachycardia | COMPLETED | NCT02666742 |
| Anti-Arrhythmics | Other | Phase PHASE4 | Arrhythmia, Cardiac | TERMINATED | NCT03035227 |
| Catheter Ablation | Other | Phase PHASE4 | Arrhythmia, Cardiac | TERMINATED | NCT03035227 |
| Anti-Arrhythmics | Other | Phase PHASE4 | Arrhythmia, Cardiac | TERMINATED | NCT03035227 |
| Catheter Ablation | Other | Phase PHASE4 | Arrhythmia, Cardiac | TERMINATED | NCT03035227 |
| Anti-Arrhythmics | Other | Phase PHASE4 | Arrhythmia, Cardiac | TERMINATED | NCT03035227 |
| Catheter Ablation | Other | Phase PHASE4 | Arrhythmia, Cardiac | TERMINATED | NCT03035227 |
| MindRhythm Harmony | Other | Preclinical | Stroke, Acute | COMPLETED | NCT04445493 |
| MindRhythm Harmony | Other | Preclinical | Stroke, Acute | COMPLETED | NCT04445493 |
| Gait Training | Other | Approved | Multiple Sclerosis | COMPLETED | NCT04314076 |
| Rhythmic auditory stimulation | Other | Approved | Multiple Sclerosis | COMPLETED | NCT04314076 |
| Gait Training | Other | Approved | Multiple Sclerosis | COMPLETED | NCT04314076 |
| Rhythmic auditory stimulation | Other | Approved | Multiple Sclerosis | COMPLETED | NCT04314076 |
| Remote Automated Monitoring System | Other | Approved | Visceral and Digestive Surgery | COMPLETED | NCT04480385 |
| Remote Automated Monitoring System | Other | Approved | Visceral and Digestive Surgery | COMPLETED | NCT04480385 |
| PURE EP (Observational Study) | Other | Preclinical | Cardiac Arrhythmias | UNKNOWN | NCT05450302 |
| PURE EP (Observational Study) | Other | Preclinical | Cardiac Arrhythmias | UNKNOWN | NCT05450302 |
| AFib detection with wearable smart watch | Other | Approved | Atrial Fibrillation | TERMINATED | NCT04499807 |
| AFib detection with wearable smart watch | Other | Approved | Atrial Fibrillation | TERMINATED | NCT04499807 |
| AQUACEL® AG | Other | Approved | Infections | COMPLETED | NCT02781779 |
| Silverlon® | Other | Approved | Infections | COMPLETED | NCT02781779 |
| AQUACEL® AG | Other | Approved | Infections | COMPLETED | NCT02781779 |
| Silverlon® | Other | Approved | Infections | COMPLETED | NCT02781779 |
| NSE Coronary Dilatation Catheter | Other | Approved | Coronary Artery Stenosis | UNKNOWN | NCT05606367 |
| Non-slip Balloon Catheter of Shanghai MicroPort Rhythm | Other | Approved | Coronary Artery Stenosis | UNKNOWN | NCT05606367 |
| Intravascular Lithotripsy System of Shanghai MicroPort Rhythm | Other | Approved | Coronary Artery Calcification | UNKNOWN | NCT05818098 |
| Intravascular Lithotripsy System of Shanghai MicroPort Rhythm | Other | Approved | Coronary Artery Calcification | UNKNOWN | NCT05818098 |
| Placebo | Other | Phase PHASE3 | Leptin Receptor Deficiency Obesity | COMPLETED | NCT03287960 |
| Setmelanotide | Other | Phase PHASE3 | Leptin Receptor Deficiency Obesity | COMPLETED | NCT03287960 |
| Placebo | Other | Phase PHASE2 | Prader-Willi Syndrome | COMPLETED | NCT02311673 |
| Setmelanotide | Other | Phase PHASE2 | Prader-Willi Syndrome | COMPLETED | NCT02311673 |
| Harmony | Other | Preclinical | Stroke, Acute | UNKNOWN | NCT05602740 |
| Harmony | Other | Preclinical | Stroke, Acute | UNKNOWN | NCT05602740 |
| Placebo | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT02041195 |
| Setmelanotide | Other | Phase PHASE1 | Overweight and Obesity | COMPLETED | NCT02041195 |
| Placebo | Other | Phase PHASE2 | Overweight | COMPLETED | NCT01749137 |
| Setmelanotide | Other | Phase PHASE2 | Overweight | COMPLETED | NCT01749137 |
| Setmelanotide | Other | Phase PHASE2 | Genetic Obesity | COMPLETED | NCT03013543 |
| Cryoballoon PVI + Posterior Wall Isolation | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT04505163 |
| Standard Cryoballoon Pulmonary Vein Isolation (PVI) | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT04505163 |
| Cryoballoon PVI + Posterior Wall Isolation | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT04505163 |
| Standard Cryoballoon Pulmonary Vein Isolation (PVI) | Other | Approved | Persistent Atrial Fibrillation | UNKNOWN | NCT04505163 |
| Active Walking | Other | Approved | Chronic Stroke | COMPLETED | NCT04121754 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT04121754 |
| Active Walking | Other | Approved | Chronic Stroke | COMPLETED | NCT04121754 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT04121754 |
| Placebo | Other | Phase PHASE3 | Pro-opiomelanocortin (POMC) Deficiency Obesity | COMPLETED | NCT02896192 |
| Setmelanotide | Other | Phase PHASE3 | Pro-opiomelanocortin (POMC) Deficiency Obesity | COMPLETED | NCT02896192 |
| Placebo | Other | Phase PHASE3 | Bardet Biedl Syndrome (BBS) | COMPLETED | NCT03746522 |
| Setmelanotide | Other | Phase PHASE3 | Bardet Biedl Syndrome (BBS) | COMPLETED | NCT03746522 |
| Conventional Atrial Septal Puncture | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT06188351 |
| Three-Dimensional Navigation Atrial Septal Puncture | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT06188351 |
| Conventional Atrial Septal Puncture | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT06188351 |
| Three-Dimensional Navigation Atrial Septal Puncture | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT06188351 |
| MultiSense® remote monitoring | Other | Approved | Visceral and Digestive Surgery | COMPLETED | NCT05357729 |
| MultiSense® remote monitoring | Other | Approved | Visceral and Digestive Surgery | COMPLETED | NCT05357729 |
| Venous Closure | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT06199414 |
| Venous Closure | Other | Preclinical | Atrial Fibrillation | UNKNOWN | NCT06199414 |
| No intervention. | Other | Preclinical | Arrhythmia | UNKNOWN | NCT06134739 |
| No intervention. | Other | Preclinical | Arrhythmia | UNKNOWN | NCT06134739 |
| No intervention. | Other | Preclinical | Arrhythmia | UNKNOWN | NCT06134739 |
| Catheter Ablation | Other | Preclinical | Atrial Fibrillation | TERMINATED | NCT05242250 |
| Kardia/AliveCor monitoring | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT04302311 |
| Holter monitoring | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT04302311 |
| Kardia/AliveCor monitoring | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT04302311 |
| Holter monitoring | Other | Approved | Atrial Fibrillation | UNKNOWN | NCT04302311 |
| Coronary Crossing System of Shanghai MicroPort Rhythm | Other | Approved | Chronic Total Occlusion of Coronary Artery | UNKNOWN | NCT05813704 |
| Coronary Crossing System of Shanghai MicroPort Rhythm | Other | Approved | Chronic Total Occlusion of Coronary Artery | UNKNOWN | NCT05813704 |
| the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd. | Other | Approved | Coronary Artery Perforation | UNKNOWN | NCT05398991 |
| the Coronary Covered Stents System manufactured by Shanghai MicroPort Medical (Group) Co., Ltd. | Other | Approved | Coronary Artery Perforation | UNKNOWN | NCT05398991 |
| SC Placebo | Other | Phase PHASE4 | Healthy | COMPLETED | NCT05046132 |
| Oral Placebo | Other | Phase PHASE4 | Healthy | COMPLETED | NCT05046132 |
| Moxifloxacin | Other | Phase PHASE4 | Healthy | COMPLETED | NCT05046132 |
| Setmelanotide | Other | Phase PHASE4 | Healthy | COMPLETED | NCT05046132 |
| Catheter ablation | Other | Phase PHASE4 | Ventricular Tachycardia (VT) | COMPLETED | NCT02830360 |
| Antiarrythmic Drug Therapy | Drug | Phase PHASE4 | Ventricular Tachycardia (VT) | COMPLETED | NCT02830360 |
| Catheter ablation | Other | Phase PHASE4 | Ventricular Tachycardia (VT) | COMPLETED | NCT02830360 |
| Antiarrythmic Drug Therapy | Drug | Phase PHASE4 | Ventricular Tachycardia (VT) | COMPLETED | NCT02830360 |
| LAmbre investigational device | Device | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06465706 |
| LAmbre investigational device | Device | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06465706 |
| leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA | Other | Preclinical | Left Atrail Appendage Closure: Peri-device Leaks | COMPLETED | NCT05131308 |
| leak closure with either detachable embolization coils, vascular plugs/CSO, or RFA | Other | Preclinical | Left Atrail Appendage Closure: Peri-device Leaks | COMPLETED | NCT05131308 |
| TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473) | Procedure | Preclinical | Aortic Stenosis | RECRUITING | NCT06055751 |
| TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473) | Procedure | Preclinical | Aortic Stenosis | RECRUITING | NCT06055751 |
| TAVR Procedure and implantation of Boston Scientific Loop Recorder (LUX-Dx PMA# K193473) | Procedure | Preclinical | Aortic Stenosis | RECRUITING | NCT06055751 |
| Persistent AF ablation assisted with the STAR Apollo Mapping System | Other | Preclinical | Persistent Atrial Fibrillation | RECRUITING | NCT05826665 |
| Persistent AF ablation assisted with the STAR Apollo Mapping System | Other | Preclinical | Persistent Atrial Fibrillation | RECRUITING | NCT05826665 |
| Coronary Sinus Lead Revision | Other | Preclinical | Heart Failure With Reduced Ejection Fraction | RECRUITING | NCT06342492 |
| Coronary Sinus Lead Revision | Other | Preclinical | Heart Failure With Reduced Ejection Fraction | RECRUITING | NCT06342492 |
| Vascular closure with LockeT device | Device | Approved | Atrial Fibrillation | RECRUITING | NCT06078735 |
| Vascular closure with LockeT device | Device | Approved | Atrial Fibrillation | RECRUITING | NCT06078735 |
| Vascular closure with LockeT device | Device | Approved | Atrial Fibrillation | RECRUITING | NCT06078735 |
| Ablation | Other | Preclinical | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06669637 |
| Ablation | Other | Preclinical | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06669637 |
| Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT04037397 |
| Anti Arrhythmics | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT04037397 |
| Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT04037397 |
| Anti Arrhythmics | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT04037397 |
| Pulmonary Vein Isolation performed by Radio Frequency Catheter Ablation | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT04037397 |
| Anti Arrhythmics | Other | Phase PHASE3 | Atrial Fibrillation | COMPLETED | NCT04037397 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06003790 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06003790 |
| Setmelanotide 30 mg | Other | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 25 mg | Other | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 20 mg | Other | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 3 mg | Other | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 2.5 mg | Other | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 2 mg | Other | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide | Other | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT04966741 |
| Pulse Oximeter, Respiratory Rate, Heart Rate | Other | Approved | Hypoxia | COMPLETED | NCT05466942 |
| Pulse Oximeter, Respiratory Rate, Heart Rate | Other | Approved | Hypoxia | COMPLETED | NCT05466942 |
| MR-010 | Other | Approved | Stroke, Acute | TERMINATED | NCT04689256 |
| MR-010 | Other | Approved | Stroke, Acute | TERMINATED | NCT04689256 |
| Rapid Rhythm Handheld 8-lead ECG Device | Device | Approved | Atrial Fibrillation | COMPLETED | NCT03501836 |
| Rapid Rhythm Handheld 8-lead ECG Device | Device | Approved | Atrial Fibrillation | COMPLETED | NCT03501836 |
| Setmelanotide | Other | Phase PHASE2 | Hypothalamic Obesity | COMPLETED | NCT04725240 |
| Standard of care | Other | Approved | Pacemaker | RECRUITING | NCT03636230 |
| Remote Monitoring | Other | Approved | Pacemaker | RECRUITING | NCT03636230 |
| Unipolar Polarity Switch Right | Other | Approved | Atrial Fibrillation | TERMINATED | NCT05464537 |
| Unipolar Polarity Switch Left | Other | Approved | Atrial Fibrillation | TERMINATED | NCT05464537 |
| Unipolar Polarity Switch Right | Other | Approved | Atrial Fibrillation | TERMINATED | NCT05464537 |
| Unipolar Polarity Switch Left | Other | Approved | Atrial Fibrillation | TERMINATED | NCT05464537 |
| No intervention or administration will be performed due to the observational nature of the study | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT06352060 |
| No intervention or administration will be performed due to the observational nature of the study | Other | Preclinical | Atrial Fibrillation | COMPLETED | NCT06352060 |
| Remote Automated Monitoring System | Other | Approved | Post ICU Rehabilitation | COMPLETED | NCT04661423 |
| Remote Automated Monitoring System | Other | Approved | Post ICU Rehabilitation | COMPLETED | NCT04661423 |
| Catheter ablation using pulsed-field ablation (PFA) system | Other | Preclinical | Atrial Fibrillation | TERMINATED | NCT06488820 |
| Catheter ablation using pulsed-field ablation (PFA) system | Other | Preclinical | Atrial Fibrillation | TERMINATED | NCT06488820 |
| Setmelanotide | Other | Phase PHASE2 | Obesity Associated With Defects in Leptin-melanocortin Pathway | COMPLETED | NCT03651765 |
| Placebo | Other | Phase PHASE3 | Hypothalamic Obesity | ACTIVE_NOT_RECRUITING | NCT05774756 |
| Setmelanotide | Other | Phase PHASE3 | Hypothalamic Obesity | ACTIVE_NOT_RECRUITING | NCT05774756 |
| Placebo | Other | Phase PHASE2 | Genetic Obesity | COMPLETED | NCT04963231 |
| Setmelanotide | Other | Phase PHASE2 | Genetic Obesity | COMPLETED | NCT04963231 |
| Market-approved AVNB, OAC and AAD | Other | Preclinical | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06783868 |
| Catheter Ablation | Other | Preclinical | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06783868 |
| Market-approved AVNB, OAC and AAD | Other | Preclinical | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06783868 |
| Catheter Ablation | Other | Preclinical | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06783868 |
| Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ) | Other | Approved | Cardiac Dysautonomia | NOT_YET_RECRUITING | NCT06672861 |
| Kansas City Cardiac Dysautonomia Questionnaire (KCDysQ) | Other | Approved | Cardiac Dysautonomia | NOT_YET_RECRUITING | NCT06672861 |
| Development of AD/OI after BS | Other | Preclinical | Autonomic Dysfunction | RECRUITING | NCT06289413 |
| Development of AD/OI after BS | Other | Preclinical | Autonomic Dysfunction | RECRUITING | NCT06289413 |
| Left Atrial Appendage Occlusion | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT06075628 |
| Left Atrial Appendage Occlusion | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT06075628 |
| Left Atrial Appendage Occlusion | Other | Preclinical | Atrial Fibrillation | RECRUITING | NCT06075628 |
| Imaging guidance with TEE and ICE for Left atrial appendage closure | Other | Approved | Atrial Fibrillation | RECRUITING | NCT06061757 |
| Imaging guidance with TEE and ICE for Left atrial appendage closure | Other | Approved | Atrial Fibrillation | RECRUITING | NCT06061757 |
| Monitoring of patients presenting with PVCs | Other | Preclinical | PVC - Premature Ventricular Contraction | RECRUITING | NCT06060548 |
| Monitoring of patients presenting with PVCs | Other | Preclinical | PVC - Premature Ventricular Contraction | RECRUITING | NCT06060548 |
| Monitoring of patients presenting with PVCs | Other | Preclinical | PVC - Premature Ventricular Contraction | RECRUITING | NCT06060548 |
| Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination | Other | Phase PHASE1 | Pain Management | NOT_YET_RECRUITING | NCT05575999 |
| Bupivacaine alone OR Bupivacaine-Ketorolac-Ketamine (BKK) Combination | Other | Phase PHASE1 | Pain Management | NOT_YET_RECRUITING | NCT05575999 |
| Masked Placebo | Other | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT05464940 |
| Intravenous caffeine | Other | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT05464940 |
| Masked Placebo | Other | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT05464940 |
| Intravenous caffeine | Other | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT05464940 |
| Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath. | Device | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT05464511 |
| Left atrial appendage occlusion with the dual mechanism closure Amulet device using a novel steerable sheath. | Device | Approved | Atrial Fibrillation | NOT_YET_RECRUITING | NCT05464511 |
| Imaging | Other | Preclinical | Myocarditis | NOT_YET_RECRUITING | NCT05139329 |
| Imaging | Other | Preclinical | Myocarditis | NOT_YET_RECRUITING | NCT05139329 |
| Imaging | Other | Preclinical | Myocarditis | NOT_YET_RECRUITING | NCT05139329 |
| Setmelanotide | Other | Phase PHASE3 | Obesity Associated With Defects in Leptin-melanocortin Pathway | ENROLLING_BY_INVITATION | NCT06596135 |
| LAAC with Watchman FLX device | Device | Preclinical | Atrial Fibrillation | TERMINATED | NCT06052358 |
| LAAC with Watchman FLX device | Device | Preclinical | Atrial Fibrillation | TERMINATED | NCT06052358 |
| MR-001 | Other | Approved | Chronic Stroke | ACTIVE_NOT_RECRUITING | NCT06051539 |
| Watchman FLX™ Pro device. | Device | Preclinical | PFA Ablation and LAAC Procedures | RECRUITING | NCT07041125 |
| Setmelanotide | Other | Phase PHASE2 | Prader-Willi Syndrome | ACTIVE_NOT_RECRUITING | NCT06772597 |
| Placebo | Other | Phase PHASE3 | Hypothalamic Obesity | RECRUITING | NCT06760546 |
| Setmelanotide | Other | Phase PHASE3 | Hypothalamic Obesity | RECRUITING | NCT06760546 |
| Genetic testing via blood collection | Other | Preclinical | Obesity, Childhood | ACTIVE_NOT_RECRUITING | NCT06239064 |
| Left Atrial Appendage Device Implant | Device | Preclinical | Atrial Fibrillation | RECRUITING | NCT06436924 |
| Ablation | Other | Preclinical | Paroxysmal Atrial Fibrillation (PAF) | ACTIVE_NOT_RECRUITING | NCT07092774 |
| Ablation | Other | Preclinical | Paroxysmal Atrial Fibrillation (PAF) | ACTIVE_NOT_RECRUITING | NCT07092774 |
| Ablation | Other | Preclinical | Paroxysmal Atrial Fibrillation (PAF) | ACTIVE_NOT_RECRUITING | NCT07092774 |
| Atrial Ablation | Other | Preclinical | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06354777 |
| Atrial Ablation | Other | Preclinical | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT06354777 |
| Pulsed Field Ablation | Other | Preclinical | Atrial Fibrillation | ENROLLING_BY_INVITATION | NCT06335082 |
| Ablation Procedure | Procedure | Preclinical | Paroxysmal Atrial Fibrillation | RECRUITING | NCT06324201 |
| Ablation Procedure | Procedure | Preclinical | Paroxysmal Atrial Fibrillation | RECRUITING | NCT06324201 |
| Arrhythmia Mapping | Other | Preclinical | Arrhythmias, Cardiac | RECRUITING | NCT06939478 |
| Arrhythmia Mapping | Other | Preclinical | Arrhythmias, Cardiac | RECRUITING | NCT06939478 |
| Arrhythmia Mapping | Other | Preclinical | Arrhythmias, Cardiac | RECRUITING | NCT06939478 |
| MR-C-014 | Other | Approved | Neuromyelitis Optica Spectrum Disorder | ENROLLING_BY_INVITATION | NCT06374264 |
| MR-C-014 | Other | Approved | Neuromyelitis Optica Spectrum Disorder | ENROLLING_BY_INVITATION | NCT06374264 |
| Part D: RM-718 | Other | Phase PHASE1 | Hypothalamic Obesity | RECRUITING | NCT06239116 |
| Part C: RM-718 | Other | Phase PHASE1 | Hypothalamic Obesity | RECRUITING | NCT06239116 |
| Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) | Other | Phase PHASE1 | Hypothalamic Obesity | RECRUITING | NCT06239116 |
| Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) | Other | Phase PHASE1 | Hypothalamic Obesity | RECRUITING | NCT06239116 |
| Bivamelagon | Other | Phase PHASE2 | Hypothalamic Obesity | ENROLLING_BY_INVITATION | NCT07156578 |
| Placebo | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05093634 |
| Setmelanotide | Other | Phase PHASE3 | Obesity | ACTIVE_NOT_RECRUITING | NCT05093634 |
| Placebo | Other | Phase PHASE2 | Hypothalamic Obesity | COMPLETED | NCT06046443 |
| LB54640 | Other | Phase PHASE2 | Hypothalamic Obesity | COMPLETED | NCT06046443 |
| Standard of Care | Other | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT03682991 |
| Aggressive Risk Factor Control | Other | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT03682991 |
| Standard of Care | Other | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT03682991 |
| Aggressive Risk Factor Control | Other | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT03682991 |
| Standard of Care | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Remote Patient Management | Other | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| Placebo | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06174220 |
| Tideglusib | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06174220 |
| Placebo | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06174220 |
| Tideglusib | Other | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06174220 |
| Monitoring by MultiSense | Other | Approved | Average Length of Stay | NOT_YET_RECRUITING | NCT07514286 |
| Monitoring by MultiSense | Other | Approved | Average Length of Stay | NOT_YET_RECRUITING | NCT07514286 |
| Monitoring by MultiSense | Other | Approved | Average Length of Stay | NOT_YET_RECRUITING | NCT07514286 |
| Monitoring by MultiSense® | Other | Approved | Reduction in the Initial Length of Stay | NOT_YET_RECRUITING | NCT07552805 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06051539 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06051539 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06051539 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06051539 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06051539 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06051539 |
| MR-001 | Other | Approved | Chronic Stroke | COMPLETED | NCT06051539 |
| Monitoring by MultiSense® | Other | Approved | Reduction in the Initial Length of Stay | NOT_YET_RECRUITING | NCT07552805 |
| Monitoring by MultiSense® | Other | Approved | Reduction in the Initial Length of Stay | NOT_YET_RECRUITING | NCT07552805 |
| Monitoring by MultiSense® | Other | Approved | Reduction in the Initial Length of Stay | NOT_YET_RECRUITING | NCT07552805 |
| Monitoring by MultiSense® | Other | Approved | Reduction in the Initial Length of Stay | NOT_YET_RECRUITING | NCT07552805 |
| Monitoring by MultiSense® | Other | Approved | Reduction in the Initial Length of Stay | NOT_YET_RECRUITING | NCT07552805 |
| Monitoring by MultiSense® | Other | Approved | Reduction in the Initial Length of Stay | NOT_YET_RECRUITING | NCT07552805 |
| Monitoring by MultiSense® | Other | Approved | Reduction in the Initial Length of Stay | NOT_YET_RECRUITING | NCT07552805 |
| Monitoring by MultiSense | DEVICE | Approved | Average Length of Stay | NOT_YET_RECRUITING | NCT07514286 |
| Bivamelagon | DRUG | Phase PHASE2 | Hypothalamic Obesity | ENROLLING_BY_INVITATION | NCT07156578 |
| Watchman FLX™ Pro device. | DEVICE | Preclinical | PFA Ablation and LAAC Procedures | RECRUITING | NCT07041125 |
| Left Atrial Appendage Device Implant | DEVICE | Preclinical | Atrial Fibrillation | RECRUITING | NCT06436924 |
| MR-C-014 | DEVICE | Approved | Neuromyelitis Optica Spectrum Disorder | ENROLLING_BY_INVITATION | NCT06374264 |
| Pulsed Field Ablation | DEVICE | Preclinical | Atrial Fibrillation | ENROLLING_BY_INVITATION | NCT06335082 |
| Part D: RM-718 | DRUG | Phase PHASE1 | Hypothalamic Obesity | RECRUITING | NCT06239116 |
| Part C: RM-718 | DRUG | Phase PHASE1 | Hypothalamic Obesity | RECRUITING | NCT06239116 |
| Part B: RM-718 or placebo (matched to specific RM-718 dose cohort) | DRUG | Phase PHASE1 | Hypothalamic Obesity | RECRUITING | NCT06239116 |
| Part A: RM-718 or placebo (matched to specific RM-718 dose cohort) | DRUG | Phase PHASE1 | Hypothalamic Obesity | RECRUITING | NCT06239116 |
| Tideglusib | DRUG | Phase PHASE2 | Arrhythmogenic Cardiomyopathy | RECRUITING | NCT06174220 |
| LB54640 | DRUG | Phase PHASE2 | Hypothalamic Obesity | COMPLETED | NCT06046443 |
| Catheter Ablation | DEVICE | Preclinical | Atrial Fibrillation | TERMINATED | NCT05242250 |
| Setmelanotide 30 mg | DRUG | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 25 mg | DRUG | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 20 mg | DRUG | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 3 mg | DRUG | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 2.5 mg | DRUG | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide 2 mg | DRUG | Phase PHASE3 | Bardet-Biedl Syndrome | COMPLETED | NCT05194124 |
| Setmelanotide, administered subcutaneously [SC], once daily. | DRUG | Preclinical | Bardet-Biedl Syndrome (BBS) | APPROVED_FOR_MARKETING | NCT05183802 |
| SC Placebo | DRUG | Phase PHASE4 | Healthy | COMPLETED | NCT05046132 |
| Oral Placebo | DRUG | Phase PHASE4 | Healthy | COMPLETED | NCT05046132 |
| Moxifloxacin | DRUG | Phase PHASE4 | Healthy | COMPLETED | NCT05046132 |
| Standard ablation power | PROCEDURE | Approved | Ventricular Tachycardia | COMPLETED | NCT04657705 |
| High power ablation | PROCEDURE | Approved | Ventricular Tachycardia | COMPLETED | NCT04657705 |
| VIRTUES | BEHAVIORAL | Approved | Atrial Fibrillation | UNKNOWN | NCT04599114 |
| Virtual Care at Home | OTHER | Approved | Covid-19 | COMPLETED | NCT04420182 |
| aCRT OFF | DEVICE | Approved | Heart Failure | COMPLETED | NCT04180696 |
| aCRT ON | DEVICE | Approved | Heart Failure | COMPLETED | NCT04180696 |
| Aggressive Risk Factor Control | OTHER | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT03682991 |
| Standard of care | OTHER | Approved | Pacemaker | RECRUITING | NCT03636230 |
| Remote Monitoring | DEVICE | Approved | Pacemaker | RECRUITING | NCT03636230 |
| KTI activities | OTHER | Approved | Atrial Fibrillation | COMPLETED | NCT03627143 |
| High-intensity interval training | BEHAVIORAL | Approved | Persistent Atrial Fibrillation | TERMINATED | NCT03467633 |
| Standard of Care | OTHER | Approved | Atrial Fibrillation | ACTIVE_NOT_RECRUITING | NCT03682991 |
| Remote Patient Management | DEVICE | Approved | Cardiac Arrhythmia | ACTIVE_NOT_RECRUITING | NCT03405740 |
| AliveCor Heart Monitor | DEVICE | Approved | Atrial Fibrillation | COMPLETED | NCT03080857 |
| Virtual Platform | OTHER | Approved | Atrial Fibrillation | COMPLETED | NCT03080857 |
| Catheter ablation | PROCEDURE | Phase PHASE4 | Ventricular Tachycardia (VT) | COMPLETED | NCT02830360 |
| Antiarrythmic Drug Therapy | DRUG | Phase PHASE4 | Ventricular Tachycardia (VT) | COMPLETED | NCT02830360 |
| Remote CIED Management | DEVICE | Approved | Arrhythmia, Cardiac | COMPLETED | NCT02585817 |
| Atomoxetine | DRUG | Phase PHASE2 | Vasovagal Syncope | COMPLETED | NCT02500732 |
| Pacing system implant with the CapsureFix MRI pacing lead model 5086 | DEVICE | Preclinical | Bradyarrhythmia | COMPLETED | NCT01522755 |
| TherapyGuide | DEVICE | Preclinical | Bradyarrhythmia | COMPLETED | NCT01513538 |
| No-CRT | OTHER | Phase PHASE4 | Heart Failure | COMPLETED | NCT01434615 |
| Model 10642 Implantable Intravascular Catheter | DEVICE | Approved | Pulmonary Arterial Hypertension | ACTIVE_NOT_RECRUITING | NCT01321073 |
| CRT-P or CRT-D | DEVICE | Approved | Heart Failure | COMPLETED | NCT01059175 |
| Additional Endocardial or Epicardial LV Lead | DEVICE | Approved | Heart Failure | COMPLETED | NCT01059175 |
| Arctic Front Cardiac Cryoablation System | DEVICE | Approved | Atrial Fibrillation | COMPLETED | NCT00889681 |
| Rate Control | OTHER | Phase PHASE4 | Atrial Fibrillation | TERMINATED | NCT00839566 |
| Ablation | DEVICE | Preclinical | Atrial Fibrillation | NOT_YET_RECRUITING | NCT06669637 |
| Advisa IPG | DEVICE | Approved | Bradycardia | COMPLETED | NCT00839384 |
| CRT | DEVICE | Phase PHASE4 | Heart Failure | COMPLETED | NCT01434615 |
| LV dp/dt pressure measurement | PROCEDURE | Phase PHASE4 | Heart Failure | COMPLETED | NCT00821938 |
| Access Arm | DEVICE | Phase PHASE4 | Heart Failure | COMPLETED | NCT00769457 |
| Upgrade to CRT | DEVICE | Preclinical | Heart Failure | COMPLETED | NCT00318357 |
| Continuation of CRT | DEVICE | Preclinical | Heart Failure | COMPLETED | NCT00318357 |
| Diagnostic | DEVICE | Preclinical | Atrial Fibrillation | COMPLETED | NCT00279981 |
| ICD | DEVICE | Preclinical | Ventricular Tachycardia | COMPLETED | NCT00279968 |
| Implanted Device | DEVICE | Approved | Tachycardia, Ventricular | COMPLETED | NCT00279279 |
| CRT-P or CRT-D Device | DEVICE | Phase PHASE4 | Heart Failure, Congestive | TERMINATED | NCT00157846 |
| RF Ablation procedure | PROCEDURE | Phase PHASE4 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT00744874 |
| Device triggered remote telephone contact because of Care Alert | BEHAVIORAL | Approved | Heart Failure | COMPLETED | NCT00730548 |
| Melody Transcatheter Pulmonary Valve | DEVICE | Approved | Heart Valve Diseases | COMPLETED | NCT00688571 |
| Usual care | OTHER | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT00673842 |
| Implantable Cardioverter Defibrillator + Usual Care | DEVICE | Phase PHASE3 | Myocardial Infarction | COMPLETED | NCT00673842 |
| Flecainide or Sotalol or Propafenone | DRUG | Phase PHASE3 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT00523978 |
| Arctic Front® Cryoablation Catheter | DEVICE | Phase PHASE3 | Paroxysmal Atrial Fibrillation | COMPLETED | NCT00523978 |
| Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool. | DEVICE | Approved | Heart Failure, Congestive | COMPLETED | NCT00400985 |
| Implantable Cardioverter Defibrillator | DEVICE | Approved | Heart Diseases | COMPLETED | NCT00328705 |
| T Wave Alternans Test | PROCEDURE | Approved | Myocardial Infarction | COMPLETED | NCT00305240 |
| Medtronic CareLink® Network | OTHER | Approved | Bradycardia | COMPLETED | NCT00294645 |
| Transtelephonic monitoring (TTM) | OTHER | Approved | Bradycardia | COMPLETED | NCT00294645 |
| Cardiac Resynchronization Therapy Device | DEVICE | Preclinical | Heart Failure | COMPLETED | NCT00291564 |
| ICD (Implantable Cardioverter Defibrillator) | DEVICE | Approved | Heart Disease | TERMINATED | NCT00281099 |
| Pacemaker | DEVICE | Preclinical | Pacemaker | COMPLETED | NCT00294034 |
| Registry | DEVICE | Preclinical | Ventricular Tachycardia | COMPLETED | NCT00270933 |
| Cardiac Resynchronization Therapy | PROCEDURE | Phase EARLY_PHASE1 | Heart Failure | COMPLETED | NCT01362465 |
| Conducted AF-Response Algorithm (CAFR) Off | DEVICE | Phase PHASE4 | Heart Failure | TERMINATED | NCT00170313 |
| Conducted AF-Response Algorithm (CAFR) On | DEVICE | Phase PHASE4 | Heart Failure | TERMINATED | NCT00170313 |
| Implantable Cardiac Resynchronisation (pacing) device | DEVICE | Approved | Heart Failure | COMPLETED | NCT00170300 |
| ICD Therapy | DEVICE | Phase PHASE4 | Tachycardia, Ventricular | COMPLETED | NCT00170287 |
| ICD Ablation plus VT-ablation | PROCEDURE | Phase PHASE4 | Tachycardia, Ventricular | COMPLETED | NCT00170287 |
| AF Prevention and Therapy Algorithms On | DEVICE | Approved | Tachyarrhythmia | COMPLETED | NCT00170274 |
| Activation of preventive and therapeutic algorithms for treatment of AF | DEVICE | Approved | Tachyarrhythmia | COMPLETED | NCT00170274 |
| Use of an Implantable Loop Recorder | DEVICE | Phase PHASE4 | Syncope | COMPLETED | NCT00170261 |
| Search AV+ algorithm | DEVICE | Phase PHASE4 | Arrhythmia, Sinus | TERMINATED | NCT00157794 |
| Medtronic AT500 | DEVICE | Phase PHASE4 | Atrial Fibrillation | COMPLETED | NCT00157781 |
| Implantable cardioverter defibrillator | DEVICE | Phase PHASE4 | Acute Myocardial Infarction | COMPLETED | NCT00157768 |
| RM-493 | DRUG | Phase PHASE1 | Overweight | COMPLETED | NCT02431442 |
| No intervention | OTHER | Preclinical | Obesity | COMPLETED | NCT01849705 |
| Placebo | DRUG | Phase PHASE3 | Hypothalamic Obesity | RECRUITING | NCT06760546 |
| Setmelanotide | DRUG | Phase PHASE2 | Prader-Willi Syndrome | ACTIVE_NOT_RECRUITING | NCT06772597 |
Total products: 541